ZFGN vs. ME, TSVT, VSTM, ACIU, PBYI, XBIT, ALDX, XERS, CDT, and QURE
Should you be buying Zafgen stock or one of its competitors? The main competitors of Zafgen include 23andMe (ME), 2seventy bio (TSVT), Verastem (VSTM), AC Immune (ACIU), Puma Biotechnology (PBYI), XBiotech (XBIT), Aldeyra Therapeutics (ALDX), Xeris Biopharma (XERS), Conduit Pharmaceuticals (CDT), and uniQure (QURE). These companies are all part of the "medical" sector.
Zafgen (NASDAQ:ZFGN) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.
23andMe has a consensus target price of $0.47, suggesting a potential upside of 1.27%. Given 23andMe's higher possible upside, analysts clearly believe 23andMe is more favorable than Zafgen.
70.4% of Zafgen shares are owned by institutional investors. Comparatively, 36.1% of 23andMe shares are owned by institutional investors. 14.2% of Zafgen shares are owned by company insiders. Comparatively, 27.6% of 23andMe shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, 23andMe had 2 more articles in the media than Zafgen. MarketBeat recorded 2 mentions for 23andMe and 0 mentions for Zafgen. 23andMe's average media sentiment score of 0.12 beat Zafgen's score of 0.00 indicating that 23andMe is being referred to more favorably in the news media.
Zafgen has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
Zafgen has higher earnings, but lower revenue than 23andMe. Zafgen is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
Zafgen received 333 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 68.59% of users gave Zafgen an outperform vote while only 63.16% of users gave 23andMe an outperform vote.
Zafgen has a net margin of 0.00% compared to 23andMe's net margin of -210.48%. Zafgen's return on equity of -51.34% beat 23andMe's return on equity.
Summary
Zafgen beats 23andMe on 8 of the 15 factors compared between the two stocks.
Get Zafgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZFGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
